Company Overview
About Omniscient Neurotechnology
Omniscient Neurotechnology (branded as o8t) is an Australian medical technology company founded in 2019 and headquartered in Sydney. Omniscient is the global pioneer of clinical connectomics — the application of brain network science to patient care. Its flagship product, Quicktome, is the world''s first FDA-cleared medical device to generate detailed maps of brain networks from standard MRI scans using artificial intelligence and machine learning. Neurosurgeons use Quicktome before life-changing brain surgeries to visualize critical functional networks (motor, language, vision, memory) and plan surgical approaches that minimize neurological damage.
Business Model & Competitive Advantage
In 2025, the National Reconstruction Fund Corporation (NRFC) led Omniscient''s Series D funding round with a $20 million preferred equity stake, with OIF Ventures co-investing, targeting a total raise of up to $36 million. Omniscient also announced a strategic partnership with The Jacobs Institute to launch the Connectomics Innovation Program, integrating connectomics into clinical research, patient care, and medical education — accelerating the translation of brain network science from research into routine clinical practice. Quicktome has US FDA clearance and is available to neurosurgery centers globally.
Competitive Landscape 2025–2026
Omniscient operates at the intersection of medical imaging, artificial intelligence, and neuroscience. Its technology processes diffusion-weighted MRI data to reconstruct white matter fiber tracts and overlay functional connectivity maps, giving surgeons a personalized atlas of each patient''s brain. The clinical connectomics field is nascent, with Omniscient holding a pioneering position. Applications extend beyond surgical planning to stroke rehabilitation, neurological disease monitoring, and neuroscience research, with the company targeting academic medical centers and high-volume neurosurgery programs worldwide.
Key Differentiators
Strong Challenger
Omniscient Neurotechnology is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Similar Brands
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Compare Omniscient Neurotechnology with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Omniscient Neurotechnology? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Omniscient Neurotechnology Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Omniscient Neurotechnology vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →